Creating antibodies to fight drug-resistant bacteria
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
This study is working on creating special antibodies that can help fight off stubborn bacteria that don't respond to regular antibiotics, with the goal of finding new ways to prevent tough infections for people who need better treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11042752 on NIH RePORTER |
What this research studies
This research focuses on developing monoclonal antibodies that target specific proteins on the surface of harmful bacteria, which are responsible for antibiotic resistance. By understanding how these bacteria adhere to human tissues, the research aims to create effective therapies that can prevent infections caused by multidrug-resistant pathogens. The approach involves advanced techniques to generate and test these antibodies, potentially leading to new treatments for infections that are currently difficult to manage.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with infections caused by multidrug-resistant bacteria, particularly those who have not responded to standard antibiotic treatments.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in developing monoclonal antibodies against bacterial infections, indicating that this approach has potential for success.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ellebedy, Ali Hassan — Washington University
- Study coordinator: Ellebedy, Ali Hassan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.